XML 63 R49.htm IDEA: XBRL DOCUMENT v3.25.2
Sale of Pegzilarginase to Immedica (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jul. 27, 2023
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Proceeds from sale of in-process research and development asset       $ 7,000 $ 0
Gain recognized within operating expenses   $ 10,000 $ 0 10,000 0
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Global Rights To Pegzilarginase          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Proceeds from sale of in-process research and development asset $ 15,000        
Contingent consideration $ 100,000        
Gain recognized within operating expenses   10,000 $ 0 10,000 $ 0
Cash received   7,000   7,000  
Receivable outstanding   $ 3,000   $ 3,000